trimethoprim/polymyxin B ophthalmic (Polytrim Ophthalmic Solution)
Classes: Antibiotics, Ophthalmic Combos
Dosing and uses of Polytrim Ophthalmic Solution (trimethoprim/polymyxin B ophthalmic)
Adult dosage forms and strengths
trimethoprim/polymyxin B
ophthalmic solution
- (1mg/10,000 units)/mL
Bacterial Conjunctivitis
Indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis and blepharoconjunctivitis
Instill 1 gtt in affected eye(s) q3hr for 7-10 days; not to exceed 6 doses/day
Pediatric dosage forms and strengths
trimethoprim/polymyxin B
ophthalmic solution
- (1mg/10,000 units)/mL
Bacterial Conjunctivitis
Indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis and blepharoconjunctivitis
<2 months: Safety and efficacy not established
≥2 years: Instill 1 gtt in affected eye(s) q3hr for 7-10 days; not to exceed 6 doses/day
Polytrim Ophthalmic Solution (trimethoprim/polymyxin B ophthalmic) adverse (side) effects
Frequency not defined
Local irritation consisting of increased redness, burning, stinging, and/or itching
Hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash
Warnings
Contraindications
Hypersensitivity
Cautions
Not for injection into the eye Not indicated for prophylaxis or treatment of ophthalmia neonatorum
Prolonged use may result in overgrowth of nonsusceptible organisms
Avoid contaminating applicator tip with material from the eye, fingers, or other source
If redness, irritation, swelling or pain persists or increases, discontinue use immediately and seek medical attention
Advise patient to not to wear contact lenses with active signs and symptoms of ocular bacterial infections or while using antibacterial eyedrops
Pregnancy and lactation
Pregnancy category: C
Lactation: Unknown whether distributed in breast milk
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Polytrim Ophthalmic Solution (trimethoprim/polymyxin B ophthalmic)
Mechanism of action
Polymyxin B: Bactericidal; causes leakage of bacterial membrane by binding to phospholipids
Trimethoprim: Bactericidal; blocks production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the enzyme dihydrofolate reductas
Indicated for ocular infections caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae, and Pseudomonas aeruginosa
